Retinal Blood Flow Decreases after Treatment with Bevacizumab for Retinopathy of Prematurity
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Authors
- Kristin Williams (ORCID: https://orcid.org/0000-0002-6469-1969)
- Abhishek Rege (ORCID: https://orcid.org/0000-0003-0955-5996)
- Joyce Wang (ORCID: https://orcid.org/0009-0007-0613-667X)
- Jason Zhou
- Avigyan Sinha (ORCID: https://orcid.org/0009-0003-0459-2445)
- Moran R. Levin (ORCID: https://orcid.org/0000-0002-1820-1623)
- Stephen Ward (ORCID: https://orcid.org/0000-0003-2375-0536)
- Sripriya Sundararajan (ORCID: https://orcid.org/0000-0001-9519-5290)
- Janet Alexander (ORCID: https://orcid.org/0000-0001-8488-4023)
- He Eun Forbes (ORCID: https://orcid.org/0000-0002-5807-0939)
- Jeong-Yoon Wu
- Ria Kapoor
- Shaiza Mansoor (ORCID: https://orcid.org/0009-0005-3694-6361)
- LS Magder
- Christina Kilby
Institutions
- University of Maryland, Baltimore (US)
- Vasoptic Medical (United States) (US)
Publication Details
- Journal
- Ophthalmology Science
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1016/j.xops.2025.100857
- Citations
- 1
- Primary Topic
- Retinopathy of Prematurity Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.36
Funders
- Maryland Industrial Partnerships
- Small Business Innovation Research
- Novartis Pharmaceuticals Corporation
- National Institutes of Health
- Small Business Innovative Research and Small Business Technology Transfer